View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 29, 2021updated 12 Jul 2022 11:21am

Syneos Health and Science 37 partner for decentralised trial delivery

Syneos Health has reached a strategic collaboration with Science 37 to enable the delivery of decentralised clinical trials.

Syneos Health has reached a strategic collaboration with Science 37 to enable the delivery of decentralised clinical trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The integration of Science 37 ’s technology-first decentralised clinical trial operating system into Syneos Health’s decentralised solutions helps to deliver such clinical trials.

Science 37 and Syneos Health will together provide a unified, seamless technology platform to biopharmaceutical sponsors to streamline their workflow.

Syneos Health ’s decentralised solutions are combined with deep behavioural and therapeutic insights and agile technologies to provide increased clinical trials access to patients and transform product development.

The company stated that Science 37 ’s premier technology platform comprises data regarding patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices and makes clinical trials virtual.

Syneos Health CEO Alistair Macdonald said: “Increasing clinical trial access and diversity is a scientific, business and ethical imperative as we continually look for ways to improve patient outcomes and eliminate healthcare disparities.

“Our powerful partnership with Science 37 adds their industry-leading platform to our Decentralized Solutions and, when combined with the mobile research nursing capabilities delivered through our Illingworth Research team, we’re able to open new pathways toward the long-sought goal of placing patients at the centre of clinical research.”

Science 37 is part of the Syneos Health Dynamic Assembly network, an open ecosystem of data and technology collaborators to deliver solutions designed to address the nuances of each customer engagement.

Syneos Health also became part of the company’s Contract Research Organization (CRO) Certified programme through this partnership.

This programme is designed to provide access, training, and commercial support to CROs to deliver decentralised clinical studies at scale.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena